Overview

This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).

Eligibility

Inclusion Criteria:

1. Patients with CD20-positive marginal zone lymphoma diagnosed by histopathology
2. First-line treatment with the combination regimen of zanubrutinib and rituximab
3. No receiving systematic treatment before enrollment
4. Having at least one measurable lesions. Measurable lesions were defined as: the longest diameter of lymph node lesions in CT cross-sectional images \> 1.5 cm, or the longest diameter of the extranodal lesion is greater than 1.0cm
5. The patients voluntarily joined this study, signed the informed consent form, had good compliance and cooperated with the follow-up.

Exclusion Criteria:

1. Other malignant tumor history or active malignant tumor need be treated
2. In addition to zanubrutinib and rituximab, other anti-tumor drug treatments were also received simultaneously (except for glucocorticoids aimed at controlling symptoms before formal treatment).